Want to see ALMS full AI Analyst Report?
Alumis Inc. (ALMS) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Esk-001 | Renal Impairment | Phase I | Recruiting | An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function | Apr 30, 2025 | ― |
| Esk-001 | Hepatic Impairment | Phase I | Recruiting | An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage | Apr 22, 2025 | ― |
| Open-Label Esk-001, Blinded Esk-001 | Psoriasis, Plaque Psoriasis, Psoriasis (Pso), Moderate Psoriasis, Severe Psoriasis | Phase III | Recruiting | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis | Jan 27, 2025 | ― |
| Apremilast, Esk-001 | Plaque Psoriasis | Phase III | Active Not Recruiting | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 | Sep 07, 2024 | ― |
| Apremilast, Esk-001 | Plaque Psoriasis | Phase III | Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis | Aug 14, 2024 | ― |
| Esk-001 | Sle | Phase II | Active Not Recruiting | Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus | Jun 29, 2023 | ― |
| Esk-001 | Plaque Psoriasis | Phase II | Active Not Recruiting | Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis | Feb 02, 2023 | ― |
| Esk-001 | Plaque Psoriasis | Phase II | Completed | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis | Oct 12, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Esk-001 | Phase I | Renal Impairment | Recruiting | An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function | Apr 30, 2025 | ― |
| Esk-001 | Phase I | Hepatic Impairment | Recruiting | An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage | Apr 22, 2025 | ― |
| Open-Label Esk-001, Blinded Esk-001 | Phase III | Psoriasis, Plaque Psoriasis, Psoriasis (Pso), Moderate Psoriasis, Severe Psoriasis | Recruiting | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis | Jan 27, 2025 | ― |
| Apremilast, Esk-001 | Phase III | Plaque Psoriasis | Active Not Recruiting | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 | Sep 07, 2024 | ― |
| Apremilast, Esk-001 | Phase III | Plaque Psoriasis | Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis | Aug 14, 2024 | ― |
| Esk-001 | Phase II | Sle | Active Not Recruiting | Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus | Jun 29, 2023 | ― |
| Esk-001 | Phase II | Plaque Psoriasis | Active Not Recruiting | Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis | Feb 02, 2023 | ― |
| Esk-001 | Phase II | Plaque Psoriasis | Completed | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis | Oct 12, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Alumis Inc. (ALMS) have in its pipeline
Alumis Inc. ALMS is currently developing the following drugs: Esk-001, Open-Label Esk-001, Blinded Esk-001, Apremilast, Esk-001. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
